Myeloid differentiation factor 88 (MyD88) is required for murine resistance to Candida albicans and is critically involved in Candida-induced production of cytokines

European Cytokine Network

Volumn 15, Issue 3, 2004, Pages 263-271

  Villamón, Eva ^a   Gozalbo, Daniel ^a   Roig, Patricia ^a   Murciano, Celia ^a   O'Connor, José Enrique ^a   Fradelizi, Didier ^b   Gil, M Luisa ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Candida albicans; IFN antibodies; IL 12p70; Murine candidiasis; MyD88; TLR; TNF

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 12; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN P70; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; FUNGAL STRAIN; FUNGAL VIRULENCE; IMMUNE RESPONSE; INFECTION RESISTANCE; INFECTION SENSITIVITY; MOUSE; MYCOSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; SIGNAL TRANSDUCTION; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE; TH1 CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, DIFFERENTIATION; CANDIDA ALBICANS; CANDIDIASIS; CYTOKINES; KIDNEY; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; NEUTROPHILS; RECEPTORS, IMMUNOLOGIC; SPLEEN; TH1 CELLS;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; MURINAE;

EID: 6344238532     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Calderone RA. 2001. Candida and candidiasis. ASM Press, New York
2. Garber G. 2001. An overview of fungal infections. Drugs. 61 (Suppl. 1): 1.
3. Romani L. 2004. Immunity to fungal infections. Nat Rev Immunol. 4: 1.
4. Puccetti P, Romani L, Bistoni F. 1995. A Th1-Th2-like switch in candidiasis; new perspectives for therapy. Trends Microbiol. 3: 237.
5. Kaposzta R, Tree P, Marodi L, Gordon S. 1998. Characterization of invasive candidiasis in gamma Interferon- and interleukin-4-deficient mice: role of macrophages in host defense against Candida albicans. Infect Immun. 66: 1708.
6. Nisini R, Romagnoli G, Gomez MJ, La Valle R, Torosantucci A, Mariotti S, Teloni R, Cassone A. 2001. Antigenic properties and processing requirements of a 65-kilodalton mannoprotein, a major antigen target of anti-Candida human T-cell response, as disclosed by specific human T-cell clones. Infect Immun. 69: 3728.
7. Mencacci A, Cenci E, Del Sero G, Fe d'Ostiani C, Mosci P, Trinchieri G, Adorini L, Romani L. 1998. IL-10 is required for development of protective Th1 response in IL-12-deficient mice upon Candida albicans infection. J Immunol. 161: 6228.
8. Mencacci A, Del Sero G, Cenci E, Fe d'Ostiani C, Bacci A, Montagnoli C, Kopf M, Romani L. 1998. Endogenous interleukin 4 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans. J Exp Med. 187: 307.
9. Montagnoli C, Bacci A, Bozza S, Gaziano R, Mosci P, Sharpe AH, Romani L. 2002. B7/CD28-dependent CD4+ CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J Immunol. 169: 6298.
10. Montagnoli C, Bozza S, Bacci A, Gaziano R, Mosci P, Morschhauser J, Pitzurra L, Kopf M, Cutler J, Romani L. 2003. A role for antibodies in the generation of memory antifungal immunity. Eur J Immunol. 33: 1193.
11. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Ann Rev Immunol. 21: 335.
12. Kopp E, Medzhitov R. 2003. Recognition of microbial infection by toll-like receptors. Curr Opin Immunol. 15: 396.
13. Takeda K, Akira S. 2004. TLR signalling pathways. Semin Immunol. 16: 3.
14. Barton GM, Medzhitov R. 2002. Control of adaptive immune responses by toll-like receptors. Curr Opin Immunol. 14: 380.
15. Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS, Vecchi A, Mantovani A, Levitz SM, Romani L. 2004. The contribution of the Toll-Like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol. 172: 3059.
16. Roeder A, Kirschning CJ, Rupee RA, Schaller M, Korting HC. 2004. Toll-like receptors and innate antifungal responses. Trends Microbiol. 12: 44.
17. Jouault T, Ibata-Ombetta S, Takeuchi O, Trinel PA, Sacchetti P, Lefebvre P, Akira S, Poulain D. 2003. Candida albicans phospholipomannan is sensed through toll-like receptors. J Infect Dis. 188: 165.
18. Villamón E, Gozalbo D, Roig P, O'Connor JE, Fradelizi D, Gil ML. 2004. Toll-like receptor 2 is essential in murine defenses against Candida albicans infections. Microb Infect. 6: 1.
19. Villamón E, Gozalbo D, Roig P, O'Connor JE, Fradelizi D, Gil ML. 2004. Toll-like receptor 2 is dispensable for acquired host immune resistance to Candida albicans in a murine model of disseminated candidiasis. Microb Infect. 6: 542.
20. Netea MG, Van der Graaf CAA, Vonk AG, Verschueren I, Van der Meer JWM, Kullberg BJ. 2002. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis. 185: 1483.
21. Netea MG, Sutmuller R, Hermann C, Van der Graaf CA, Van Der Meer JW, Van Krieken JH, Hartung T, Adema G, Kullberg BJ. 2004. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol. 172: 3712.
22. Marr KA, Balajee SA, Hawn TR, Ozinsky A, Pham U, Akira S, Aderem A, Liles C. 2003. Differential Role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun. 71: 5280.
23. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 9: 143.
24. Gil-Navarro I, Gil ML, Casanova M, O'Connor JE, Martinez JP, Gozalbo D. 1997. The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase of Candida albicans is a surface antigen. J Bacteriol. 179: 4992.
25. Gozalbo D, Gil-Navarro I, Azorin I, Renau-Piqueras J, Martinez JP, Gil ML. 1998. The cell wall-associated glyceraldehyde-3-phosphate dehydrogenase of Candida albicans is also a fibronectin and laminin binding protein. Infect Immun. 66: 2052.
26. De Bernardis F, Adriani FD, Lorenzini R, Pontieri E, Carruba G, Cassone A. 1993. Filamentous growth and elevated vaginopathic potential of a non-germinative variant of Candida albicans expressing low-virulence in systemic infection. Infect Immun. 61: 1500.
27. Netea MG, Van Tits LJH, Curfs JHAJ, Amiot F, Meis JFGM, Van der Meer JWM, Kullberg BJ. 1999. Increased susceptibility of TNF-α lymphotoxin-α double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida. J Immunol. 163: 1498.
28. Chiani P, Bromuro C, Torosantucci A. 2000. Defective induction of interleukin-12 in human monocytes by germ-tube forms of Candida albicans. Infect Immun. 68: 5628.
29. Liu L, Kang K, Takahara M, Cooper KD, Ghannoum MA. 2001. Hyphae and yeasts of Candida albicans differentially regulate interleukin-12 production by human blood monocytes: inhibitory role of C. albicans germination. Infect Immun. 69: 4695.
30. Fe d'Ostiani C, Del Sero G, Bacci A, Montagnoli C, Spreca A, Mencacci A, Ricciardi-Castagnoli P, Romani L. 2000. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans: implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med. 191: 1661.
31. Romani L, Montagnoli C, Bozza S, Perruccio K, Spreca A, Allavena P, Verbeek S, Calderone RA, Bistoni F, Puccetti P. 2004. The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. Int Immunol. 16: 149.
32. Romani L, Mocci S, Bietta C, Lanfaloni L, Puccetti P, Bistoni F. 1991. Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun. 59: 4647.
33. Romani L, Mencacci A, Cenci E, Mosci P, Vitellozzi G, Grohmann U, Puccetti P, Bistoni B. 1992. Course of primary candidiasis in T-cell depleted mice infected with attenuated variant cells. J Infect Dis. 166: 1384.
34. Romani L, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Puccetti P, Bistoni F. 1993. CD4+ subset expression in murine candidiasis. J Immunol. 150: 925.
35. Han Y, Cutler JE. 1995. Antibody response that protects against disseminated candidiasis. Infect Immun. 63: 2714.
36. Bromuro C, Torosantucci A, Chiani P, Conti S, Polonelli L, Cassone A. 2002. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of Candida albicans vaccine. Infect Immun. 70: 5462.
37. Matthews R, Burnie J. 2001. Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs. 2: 472.
38. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrobial Agents Chemother. 47: 2208.